Kornimate/medical-research-clean huggingface dataset:
km3d multicenter cancer consortium: predicting patient response using 3d cell culture models

Conditions: Cancer; Predictive Cancer Model; Effects of Chemotherapy

Summary: this study will assess the ability of the known medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.

this is a non-interventional clinical study in which (1) cancer tissue that has been resected, biopsied, or drained due to malignant pleural effusion and that is left remaining after (or is not being used during) a pathology investigation and, where possible, (2) a vial of the same patient's blood is sent to known medicine inc. for placement into organoids and subsequent tumor drug sensitivity measurement. patients will be consented prior to performance of a medically indicated and pre-planned surgical procedure during which at least a 1cm3 piece of tumor tissue or \>100 ml pleural effusion fluid and blood in a separate vial are obtained. these samples will be sent after removal to known medicine inc. from the hospital using a kit provided by known medicine. within the known medicine provided kit a data form, freezer pack and containers for the specimens will be provided. if a solid tissue sample, the tissue will be washed and subsequently digested into a single cell solution using enzymatic digestion methods. cells will be sorted into cancer and stromal cell populations, stained fluorescently with intramembrane stain, and placed into a 3d cell culture matrix within a multi-well plate. cells may also be genetically sequenced. if an aspirated fluid sample, cells will be separated from the fluid and further sorted into cancer cell populations. cultures will be allowed to sustain themselves for 48 hours, at which point standard of care chemotherapeutic or other fda approved drug treatments will be administered. after 72 hours, control and treated wells will be imaged using fluorescence and cell phenotype will be evaluated. media from cultures may also be evaluated. after imaging, media will be removed and a metabolic assay will be performed to determine culture viability. using the described quantitative outcomes, tumor sensitivity to each of the administered treatments will be determined. patients will be followed and their response to treatment and outcome information from the hospital will be obtained which will allow retrospective validation of tumor organoid sensitivity.

Eligibility criteria:
inclusion criteria: * a demonstrated primary solid cancer for which it is medically indicated and planned to be surgically resected, biopsied, or drained (via malignant pleural effusion). * the ability to ship the tissue sample within 24 hours of removal from the patient. * signed and dated consent to giving tissue as well as allowing for de-identified medical history information regarding administered treatments and treatment outcomes to be shared. * over 18 years of age exclusion criteria: * presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation in the opinion of the investigator.
safety of 6 hours feeding after extracorporeal shock wave lithotripsy of pancreatic stone

Conditions: Pancreatic Duct Stone; ESWL; Fasting

Summary: the purpose of this study is to evaluate the safety of eating 6 hours after extracorporeal shock wave lithotripsy (eswl). at present, eswl and endoscopic retrograde cholangiopancreatography (ercp) are the routine ways to treat pancreatic duct stones. for large stones (diameter \> 5mm) , eswl often needs to be performed many times. in clinical practice, fasting for 24 hours after surgery is often used, but long-term fasting brings strong discomfort to patients. however, the consensus for initiation timing of oral nutrition has not yet been established after eswl. thus, we design this trial to evaluate the safety of early feeding based on 6 hours parameter instead of the consensus definition.

in recent years, studies have shown that early recovery of enteral nutrition has significant benefits for patients. early recovery of oral feeding and drinking as well as early oral supplementary nutrition after surgery can promote the recovery of intestinal motor function, help maintain intestinal mucosal function, prevent postoperative flora disorder and diarrhea, shorten postoperative hospital stay, and improve postoperative anxiety of patients.this study mainly evaluated the safety of feeding 6 hours after eswl, including the risk of post-eswl pancreatitis and other adverse events, as well as the length of hospital stay, medical expenses, pain, etc. this research conclusion is helpful to provide more scientific and reasonable fasting time for patients after eswl, improve patient comfort, reduce the risk of adverse events, shorten hospital stay, save medical expenses, and guide clinical practice.

Eligibility criteria:
inclusion criteria: * patients with chronic pancreatitis who completed eswl. exclusion criteria: * readmitted to the hospital during enrollment of the study; * cannot eat or rely on jejunal nutrition tube to give total parenteral nutrition for various reasons; * with acute pancreatitis, perforation, infection, bleeding, steinstrasse and other complications and other serious clinical adverse events within 6 hours after eswl; * suspected or confirmed malignancy * pancreatic ascites; * coagulation dysfunction; * taking chemotherapy drugs and immunosuppressants for a long time; * acute pancreatitis exacerbation or acute exacerbation of chronic pancreatitis (including biliary pancreatitis); * pregnant or breastfeeding women; * patients who refused to participate in the study.
effect of glycopyrrolate and atropine on catheter-related bladder discomfort

Conditions: Catheter Site Discomfort; Complications; Anesthesia; Urinary Bladder Neoplasms

Summary: we want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.

the mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. the adjuncts to reversal agents such as glycopyrrolate and atropine are known to block the muscarinic receptor in different ways. we want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.

Eligibility criteria:
inclusion criteria: * patients scheduled for transurethral bladder excision under general anesthesia * asa i-iii exclusion criteria: * foley catheter less than 18 fr. * patients with obstruction of urinary tract * patients with neurogenic bladder * patients with severe obesity * patients with neurologic disorder * patients with chronic pain * patients with allergic history to atropine or glycopyrrolate
efficacy and safety of bali association in the treatment of aphthous ulcerations

Conditions: Aphthous Stomatitis

Summary: the purpose of this study is to evaluate the efficacy and safety of bali association in the treatment of aphthous ulceration.


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * age greater than or equal to 12 years; * minor recurrent aphthous ulceration with onset of symptoms within 48 hours; * moderate to severe baseline pain, with vas ≥ 4 (eva scale). exclusion criteria: * any clinical findings that, in the judgment of the investigator, may interfere with the safety of research participants; * participants diagnosed with: behcet's disease, rheumatoid arthritis, systemic lupus erythematosus, reactive arthritis, reiter's syndrome, crohn's disease, ulcerative colitis); * participants with diseases that affect healing (e.g. diabetes); * immunocompromised participants; * participants with aphthous herpetiform ulceration or major aphthous ulceration; * participants using medication to treat oral ulcerations (systemic or local); * participants who used analgesics or anti-inflammatory drugs in the 6 hours prior to the beginning of the study; * participants who used systemic antibiotics in the 2 weeks prior to the beginning of the study; * participants using medications that can confuse pain assessment (psychotropics, antidepressants and sedative-hypnotics), except when on a stable dose for at least 30 days prior to the screening visit, and the dose cannot be changed during the clinical trial; * participants with current smoking habits. * participants who are pregnant, breastfeeding or planning to get pregnant or female participants with the potential to become pregnant who are not using a reliable method of contraception; * known hypersensitivity to the formula components used during the clinical trial; * participants with current or medical history of cancer in the last 5 years; * participants who participated in other research protocol in the last 12 months, unless the investigator judges that there may be a direct benefit to it.

Keywords: aphthous stomatitis
study of retinal and choriocapillary vascular changes in patients undergoing tadalafil 20mg for more than 6 months

Conditions: Erectile Dysfunction Following Radical Prostatectomy

Summary: this study evaluates the retinal and choriocapillary vascular features in patients under the effects of tadalafil 20mg for more than 6 months, using optical coherence tomography angiography.

tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood flow to the penis thus promoting the erection. this drug represents an treatment for erectile dysfunction in patients after radical prostatectomy. the optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features. the study evaluates the changes in optical coherence tomography angiography features after the somministration of tadalafil 20 mg orally for more than 6 months.

Eligibility criteria:
inclusion criteria: * age older than 45 years * diagnosis of erectile dysfunction due to surgery of radical prostatectomy * treatment-naïve with tadalafil for erectile dysfunction for more than 6 months * absence of diabetes, heart diseases, hypertension * absence of drug intake * absence of vitreoretinal, vascular retinal diseases * absence of previous ocular surgery and congenital eye diseases. * absence of errors of refraction * absence of lens opacities * absence of low-quality oct and octa images exclusion criteria: * age younger than 45 years * diagnosis of erectile dysfunction due to other causes * previous treatments before tadalafil for erectile dysfunction * presence of diabetes, heart diseases, hypertension * drug intake * vitreoretinal and vascular retinal diseases * previous ocular surgery and congenital eye diseases * errors of refraction * lens opacities * low-quality oct and octa images
a dose-finding and confirmatory trial of opc-6535 in patients with active crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to verify the safety and efficacy of opc-6535 and determine the optimal dose by once-daily oral administration of opc-6535 at 25 or 50 mg or placebo for 8 weeks in combination with base treatment (either a fixed oral dose of 5-aminosalicylic acid \[5-asa\] or a fixed oral dose of 5-asa plus enteral nutrition) in 180 patients with active crohn's disease.


Eligibility criteria:
inclusion criteria: * primary lesion in either small intestine or large intestine * c-reactive protein (crp) level above the upper limit of the normal range * patients who have been receiving a 5-asa formulation (oral mesalazine) at a fixed dose of 2.25 g/day or higher (not exceeding the approved dose) and at a fixed dosing regimen * patients who have not received enteral nutrition or who have been receiving enteral nutrition at a fixed intake of 1200 kcal/day or less exclusion criteria: * patients with an uncontrolled external fistula (including anal fistula) * patients with a history of total proctocolectomy or subtotal colectomy * patients with short bowel syndrome * patients with an artificial anus * patients with serious infectious disease (intra-abdominal abscess, etc) * patients with malignant tumor * female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the trial period
effect of platelet-rich plasm (prf) on two-implant mandibular overdenture: a split mouth

Conditions: Edentulous Jaw; Dental Implant Failed

Summary: implant retained overdentures are a cost-effective treatment for elderly patients suffering from complete tooth loss. despite the high success rate of implants in the general population, older adults lacking all teeth are a challenging population for implant therapy, often presenting limited bone disponibility, narrow alveolar ridges, diminished bone density, scarce inserted gingiva and several co-morbidities.thus, improving their possibility of success in implant therapy avoiding further surgical interventions is key. platelet-rich fibrin (prf) is a blood derivate that can be easily and economically obtained from patients and that has shown promise of reducing the complications and improving the success of implant therapy, nevertheless its benefits in patients receiving implant retained overdentures has not been stablished. it is possible that prf can improve the results and diminish the complications of implant therapy in older adults. the investigation aims to demonstrate that the use of platelet-rich fibirn (prf) is safe and beneficial for implant treatment in older adults suffering from complete tooth loss.

the investigators will conduct a split-mouth design randomized clinical trial assessing the effect of prf in primary stability and bone/soft tissue healing around mandibular implants in edentulous elderly adults. aim and purpose 1. to assess the effect of prf on primary implant stability of mandibular implants in edentulous patients using resonance frequency analysis (rfa). 2. to evaluate the effect of prf on clinical parameters related to soft tissue healing, post-surgical pain/inflammation and early complications of mandibular implants in edentulous patients. 3. to examine soft tissues volumetric changes pre and post- surgery using intraoral scans and bone changes using cone-beam computed tomography (cbct) around mandibular implants in edentulous patients.

Eligibility criteria:
inclusion criteria: * mandibular edentulous * \> 60 years old exclusion criteria: * physical or psychological impediment for dental surgery * dental extraction \< 6 months in the mandible * anticoagulant treatment

Keywords: dental implants platelet-rich plasm edentulous jaw
development of a global scale assessing impairment in cerebral small vessel diseases

Conditions: Small Vessel Cerebrovascular Disease

Summary: in daily practice, several scales are used to evaluate patients with small vessel diseases of the brain (svd). however, these scales exclude key symptoms such as apathy and mood disorders observed in svd. furthermore, the use of a combination of scales does not allow neither a very sensitive assessment of clinical changes, neither an overall assessment of a patient's outcome. moreover, there is no scale dedicated to cognitive, emotional and behavioural complaints in patients with svd. these patients are evaluated with scales used in neurodegenerative diseases such as alzheimer's disease and frontotemporal dementia. these are scales that have been developed in the elderly and they are not sensitive to minor complaints. it is needful to develop scales adapted to patients with svd in order to understand the consequences of the disease symptoms on their daily life at inclusion and during follow-up.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * french mother language * french reading and writing * the patient can fulfil the questionnaire on his own, without any help. * brain imaging suggestive of svd: confluent white matter hypersignals with symmetric distribution, small deep infarction, cerebral haemorrhage, microbleeds optional: • presence of informative companion in contact with the patient at least once every 15 days exclusion criteria: * presence of unacquired cognitive impairment (mental retardation, developmental disorders) * presence of non-vascular leukoencephalopathy * clinical picture and evolution suggesting a degenerative disease * serious or unstable psychiatric problems (psychoses, severe depression) * unstable clinical status
efficacy of virtual reality exercises on sarcopenia in patients with liver transplantation

Conditions: Sarcopenia

Summary: this study will be conducted to investigate the effect of virtual reality exercises on hand grip strength, pinch strength, quadriceps muscle strength, exercise capacity, fatigue, and quality of life in patients with liver transplantation.

liver transplantation (lt) continues to prove to be the best choice for curing patients with end-stage liver disease (esld) . management strategies in peri-transplantation care have significantly improved the outcomes of patients after lt. one of the most challenging tasks of lt is defining which patients are clinically appropriate for this therapy. evaluating disease severity for patients with esld is a serious challenge for liver transplant surgeons, and there is a critical need for better methods of risk stratification. the most common complications involved include ascites, hepatic encephalopathy, and variceal bleeding; however, severe muscle wasting or sarcopenia is the most common and frequently undiagnosed complications that negatively impact survival, quality of life, and response to stressors, such as infections and surgeries. virtual reality (vr) is an interactive, 3-dimensional computer experience occurring in real time. it allows the users to participate in multisensory and multidimensional virtual environments . it provides the participants with real-time auditory, visual, and proprioception sensory feedback. it also provides a safe virtual exercise environment. sixty patients with liver transplantation will be assigned randomly to two groups; experimental group will receive virtual reality exercise plus traditional therapy for six weeks, control group will receive traditional therapy alone for six weeks

Eligibility criteria:
inclusion criteria: sixty patients suffer from sarcopenia with liver transplantation. the age of patients ranges from (18:65) years. all patients must be conscious. patients suffer from muscle weakness patients suffer from fatigue patients with low muscle endurance patients' cases must be stable to deal with them exclusion criteria: patients will be excluded if they have any of the following: any sign of acute rejection of the transplanted organ acute hemorrhage electrolyte imbalance physiological instability sever neurologic complication sever cardiovascular co-morbidities

Keywords: liver transplantation virtual reality quality of life
histiocytosis and inflammatory manifestations in patients with h syndrome

Conditions: H Syndrome

Summary: h syndrome is a rare genetic disorder predisposing to histiocytosis. our knowledge of the clinical spectrum of these patients is based on case reports and small patient series. patients with h syndrome have been treated with a range of immunomodulatory and chemotherapeutic agents, with limited success. we aim to comprehensively assess the clinical manifestations and patterns of treatment response in a multinational cohort of patients with h syndrome.

h syndrome is a rare inflammatory genetic disorder predisposing to histiocytosis, caused by germline biallelic loss-of-function mutations in slc29a3, encoding the protein equilibrative nucleoside transporter 3 (ent3). ent3 transports nucleosides from lysosomes to the cytoplasm following lysosomal degradation of nucleic acids. results from our previous study (under review) suggest a model in which impaired nucleoside trafficking aberrantly activates nucleoside-sensing toll-like receptors, leading to persistent activation of erk, driving histiocytosis. this constitutes a novel signaling pathway leading to activation of erk and histiocytosis, in the absence of somatic mutations in mapk cascade genes. our knowledge of the heterogenous clinical spectrum of these patients is based on case reports and small patient series. patients with h syndrome have been treated with a range of immunomodulatory and chemotherapeutic agents, with limited success. improvement following therapy with tocilizumab, an il6-receptor antibody, has recently been reported in isolated case reports. there is a lack of data on mek inhibitor therapy in these patients. we aim to comprehensively assess the clinical manifestations and patterns of treatment response in a multinational cohort of patients with h syndrome.

Eligibility criteria:
inclusion criteria: any patient with a genetically confirmed diagnosis of h syndrome - exclusion criteria: -

Keywords: slc29a3
mindful walking in low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to determine whether a mindful walking program is effective in the treatment of patients with chronic low back pain.


Eligibility criteria:
inclusion criteria: * male and female, 18-65 years * chronic low back pain (disease duration \> 3 months) * pain intensity on visual analogue scale at inclusion \> 40 mm (0-100 mm scale) * only pharmacological treatment with nsaid or no treatment in the last 4 weeks * undersigned informed consent form exclusion criteria: * active walking or jogging in the last 6 weeks (\< 60 minutes/week) * regular meditation, relaxation exercise, mindfulness exercise in last 6 weeks (\> 30 minutes per week) * use of complementary medicine therapies as acupuncture, homeopathy, herbal medicine in last 6 weeks or planned in the next 12 weeks * use of other nonpharmacological therapies as physical therapy, manual therapy or osteopathy in the last 4 weeks * participation in another trials within the last 3 months * pathological neurological symptoms such as muscular paralysis or paraesthesia due to spinal disc herniation or other causes * risk of falls and inability to walk * angina pectoris in the last 3 months * chronic respiratory disease with respiratory insufficiency * intake of central nervous system-acting analgesics in the last 6 weeks * known renal and / or hepatic diseases * severe organic, psychological or psychiatric disorders that are not permitting a study participation * applying for early retirement due to low back pain * no undersigned informed consent form